Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Transplant-Ineligible Myeloma and MRD Integration: Current Definitions and Future Directions
Saad Z. Usmani, MD, MBA, FACP, discusses how the definition of the transplant-ineligible population for multiple myeloma is evolving while also addressing the challenges of standardizing minimal residual disease (MRD) as a biomarker across various treatment settings and clinical trials to ensure consistent and reliable use in treatment decision-making.
EP: 1.Early Intervention in High-Risk Smoldering Myeloma: Results From the AQUILA Study at ASH 2024
EP: 2.Exploring the Frontline Potential of Teclistamab: Insights From MajesTEC-5 at ASH 2024
EP: 3.MRD Outcomes From CEPHEUS at ASH 2024
Now Viewing
EP: 4.Transplant-Ineligible Myeloma and MRD Integration: Current Definitions and Future Directions
EP: 5.Anitocabtagene Autoleucel in Focus: Insights From the iMMagine-1 Trial at ASH 2024
EP: 6.Advancing Multiple Myeloma Care: Insights From ASH 2024 and Beyond
Video content above is prompted by the following:
- What, in your opinion, is the definition of the transplant-ineligible population for multiple myeloma?
- With the growing use of MRD as a biomarker, what challenges remain in standardizing its use across different treatment settings and trials?
Related Videos
Related Content
ICYMI: Highlights From AMCP Nexus 2024
December 26th 2024Article
Check out this year's top coverage from The Academy of Managed Care Pharmacy (AMCP) Nexus 2024 meeting, which included relevant topics in health care policy, novel pharmaceutical developments, financial considerations across multiple conditions, and more.
Read More
